Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

av Passaro A, Lazzari C, Karachaliou N, Spitaleri G, Pochesci A, Catania C, Rosell R, de Marinis F
Publicerad 2016-10-01

Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma

av De Pas, T, Spitaleri, G, Vigna, PD, Toffalorio, F, Curigliano, G, Gambino, A, Boselli, S, Catania, C, de Braud, F
Publicerad 2008

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

av Spitaleri G, Biffi R, Barberis M, Fumagalli C, Toffalorio F, Catania C, Noberasco C, Lazzari C, de Marinis F, De Pas T
Publicerad 2015-08-01

QTc prolongation assessment in anticancer drug development: clinical and methodological issues

av Curigliano, G, Spitaleri, G, de Braud, F, Cardinale, D, Cipolla, C, Civelli, M, Colombo, N, Colombo, A, Locatelli, M, Goldhirsch, A
Publicerad 2009

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

av Catania C, Conforti F, Spitaleri G, Barberis M, Preda L, Noberasco C, Lazzari C, Toffalorio F, de Marinis F, Manzotti M, De Pas TM
Publicerad 2014-05-01

Gene expression profiling reveals GC and CEACAM1 as new tools in the diagnosis of lung carcinoids

av Toffalorio, F, Belloni, E, Barberis, M, Bucci, G, Tizzoni, L, Pruneri, G, Fumagalli, C, Spitaleri, G, Catania, C, Melotti, F, Pelicci, P G, Spaggiari, L, De Pas, T
Publicerad 2014